Activities

The Laboratory of Oncolytic-Virus-Immuno-Therapeutics (LOVIT) is a strategic alliance between LIH and the German Cancer Research Centre (DKFZ) established in 2016 to advance research on oncolytic virus immunotherapy. 

Research projects

The LOVIT research unit mainly focuses on oncolytic rat parvovirus H-1 (H-1PV) which is not pathogenic for humans and possesses oncolytic and oncosuppressive properties.

The research program of LOVIT builds on recent pioneering studies and more specifically on the development ofa first generation of Ad-PV chimeras in which an engineered version of the H-1PV genome was inserted into the Ad5 genome. This  study showed that :

  • The Ad carrier serves as a Trojan horse to efficiently bring the PV-genome into cancer cells,
  • The PV DNA gets excised from the Ad backbone and initiates a genuine PV cycle in an autonomous way.

As a result, the chimeras were shown to be able to specifically infect and kill cancer cells by their cytolytic activity and to produce PV particles able to invade and further propagate into neighboring cancer cells inducing secondary rounds of lytic infection.  

The Ad-PV chimera represents an innovative anticancer agent that can be further improved (e.g. through arming with therapeutic transgenes) and/or combined with other anticancer modalities (e.g. immunotherapy) to enhance antitumour potential.The construction of second generation chimera and the rational design of Ad-PV chimera based combination strategies are the main goals of LOVIT. 

The ambition of the research unit is to produce the necessary proof(s)-of- concept necessary to move most promising therapies from the bench into the clinic.

Featured Publications

A roadmap for the success of oncolytic parvovirus-based anticancer therapies.

  • Laboratory of Oncolytic-Virus-Immuno-Therapeutics
June 29, 2020
2020 Jun. Annu Rev Virol. Online ahead of print.
By:
  • Hartley A
  • Kavishwar G
  • Salvato I
  • Marchini A.

Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects.

  • Laboratory of Oncolytic-Virus-Immuno-Therapeutics
February 06, 2020
2020 Feb. Neurooncol Adv.2(1):vdaa013.
By:
  • Hossain JA
  • Marchini A
  • Fehse B
  • Bjerkvig R
  • Miletic H.

Immune conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study.

  • Laboratory of Oncolytic-Virus-Immuno-Therapeutics
August 07, 2019
2019 Aug. Front Immunol.10:1848.
By:
  • Marchini A
  • Daeffler L
  • Pozdeev VI
  • Angelova A
  • Rommelaere J.
See all publications

Contacts

Antonio Marchini

Ph.D.

84, rue Val Fleuri
L-1526Luxembourg
Luxembourg
Tel. : +352 26970-856